NCT02384902

Brief Summary

low GI and low GL diet have more beneficial effect for diabetic nephropath patients compared with conventional diet. low GL may have more favorable effect than low GI diet.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started May 2014

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2014

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2014

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 6, 2014

Completed
6 months until next milestone

First Posted

Study publicly available on registry

March 10, 2015

Completed
Last Updated

March 10, 2015

Status Verified

March 1, 2015

Enrollment Period

2 months

First QC Date

September 6, 2014

Last Update Submit

March 9, 2015

Conditions

Keywords

glycemic indexdiabetic nephropathylow glycemic loadinflammation

Outcome Measures

Primary Outcomes (1)

  • Serum creatinine (and blood urea nitrogen (BUN) (mg/dL) were measured by colorimetric method and enzymatic colorimetric method using commercial assay kit.

    baseline, wk 12

Secondary Outcomes (1)

  • Serum levels of high sensitive C- reactive protein (hs-CRP) (mg/L) were quantified by using an ultrasensitive latex-enhanced immunoturbidimetric assay (Randox Laboratory Ltd., Belfast, United Kingdom).

    baseline, wk 12

Other Outcomes (1)

  • Fasting blood sugar (FBS) and lipid profile concentrations (mg/dl) were measured using commercially available enzymatic reagents adopted to an auto-analyzer system.

    baseline, wk 12

Study Arms (3)

low GI

EXPERIMENTAL

low GI: participants were asked to consume low GI foods (GI\<55) in abundant, medium GI in moderate and high GI (GI\>70) rarely.

Other: low GI

low GL

EXPERIMENTAL

low GL: participants were asked to consume low GI foods and the amount of carbohydrate was controlled.

Other: low GI

conventional diet

EXPERIMENTAL

conventional diet: all carbohydrate were treated as the same.

Other: conventional diet

Interventions

low GIOTHER

All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.

low GI

All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.

conventional diet

Eligibility Criteria

Age30 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • diabetic nephropathy, medication stable

You may not qualify if:

  • poor adherence of dietary recommendations, any changes in kind or dosage of medications

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Leila Azadbakht

Isfahan, Isfahan, Iran

Location

MeSH Terms

Conditions

Diabetic NephropathiesMedication AdherenceInflammation

Condition Hierarchy (Ancestors)

Kidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System DiseasesPatient CompliancePatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehaviorPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • leila azadbakht, phd

    Isfahan University of Medical Sciences

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Leila Azadbakht

Study Record Dates

First Submitted

September 6, 2014

First Posted

March 10, 2015

Study Start

May 1, 2014

Primary Completion

July 1, 2014

Study Completion

July 1, 2014

Last Updated

March 10, 2015

Record last verified: 2015-03

Locations